21st Jun 2024 06:55
OptiBiotix Health PLC - York, England-based life sciences company - On Thursday, notes that study outcomes at Roehampton University in London suggested the company's SlimBiome "had a major impact on insulin response combined with significantly lower feelings of hunger, a lower desire to eat, and significantly higher levels of fullness within 15 minutes, for over two hours after consumption".
SlimBiome is a mix of konjac root, fructo-oligosaccharide and chromium and is available among others as a snack bar and gummies and is also used by sports nutrition brands.
Chief Executive Officer Stephen O'Hara says: "We're delighted to see these study results which continue to prove the efficacy of Slimbiome to reduce hunger and food cravings which changes the amount and type of food people eat leading to sustainable weight management. The current anti-obesity drugs available on the market are not suitable for everyone, and Slimbiome represents a natural alternative that can be widely used with no adverse side effects."
Current stock price: 16.00 pence each, closed 1.5% lower on Thursday in London
12-month change: up markedly from 7.25p at June 21, 2023
By Tom Budszus, Alliance News slot editor
Comments and questions to [email protected]
Copyright 2024 Alliance News Ltd. All Rights Reserved.
Related Shares:
OptiBiotix Health